The Expression of in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy.

The altered expression of in patients with gastric cancer has been reported frequently, yet its correlation to prognosis and chemotherapy needs to be unveiled. In combination of the gene expression data retrieved from TCGA database and bioinformatic analysis, this study discovered 590 differentially expressed genes in the cancerous biopsies isolated from gastric patients, compared with controls. Among which, exhibited great potential to serve as a prognostic biomarker for gastric patients; furthermore, patients with low expression of could be more sensitive to these 9 chemotherapeutic agents: A-770041, AMG-706, ATRA, BEZ235, bortezomib, CGP60474, dasatinib, HG-64-1, and pazopanib, rather than the other chemotherapeutic agents.

Erratum to comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor.

[This corrects the article DOI: 10.21037/atm-20-6047.].

Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor.

Background: Differential expression of tumor protein 53 (TP53, or p53) has been observed in multiple cancers. However, the expression levels and prognostic role of TP53 signaling pathway genes in Wilms' tumor (WT) have yet to be fully explored.

Methods: The expression levels of TP53 signaling pathway genes including TP53, mouse double minute 2 (MDM2), mouse double minute 4 (MDM4), cyclin-dependent kinase 2A (CDKN2A), cyclin-dependent kinase 2B (CDKN2B), and tumor suppressor p53-binding protein 1 (TP53BP1) in WT were analyzed using the Oncomine database.